Loomis Sayles & Co. L P Raises Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Loomis Sayles & Co. L P lifted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 29.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 808 shares of the medical equipment provider’s stock after purchasing an additional 183 shares during the quarter. Loomis Sayles & Co. L P’s holdings in Hologic were worth $66,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Janus Henderson Group PLC boosted its stake in Hologic by 29.5% in the first quarter. Janus Henderson Group PLC now owns 99,707 shares of the medical equipment provider’s stock worth $7,773,000 after buying an additional 22,732 shares in the last quarter. B. Riley Wealth Advisors Inc. boosted its stake in Hologic by 13.0% in the first quarter. B. Riley Wealth Advisors Inc. now owns 3,198 shares of the medical equipment provider’s stock worth $249,000 after buying an additional 367 shares in the last quarter. Tidal Investments LLC boosted its stake in Hologic by 10.8% in the first quarter. Tidal Investments LLC now owns 16,901 shares of the medical equipment provider’s stock worth $1,317,000 after buying an additional 1,654 shares in the last quarter. Comerica Bank boosted its stake in Hologic by 40.9% in the first quarter. Comerica Bank now owns 110,053 shares of the medical equipment provider’s stock worth $8,580,000 after buying an additional 31,967 shares in the last quarter. Finally, iA Global Asset Management Inc. purchased a new stake in Hologic in the first quarter worth approximately $37,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Price Performance

Shares of Hologic stock opened at $79.44 on Friday. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The company has a market cap of $18.45 billion, a PE ratio of 23.86, a P/E/G ratio of 2.51 and a beta of 0.98. The business has a 50 day moving average of $80.28 and a 200 day moving average of $78.42. Hologic, Inc. has a 52 week low of $67.59 and a 52 week high of $84.67.

Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting analysts’ consensus estimates of $1.01. The company had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.89 earnings per share. As a group, equities research analysts forecast that Hologic, Inc. will post 4.27 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on HOLX. Raymond James upped their target price on Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 5th. UBS Group boosted their price objective on Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Evercore ISI boosted their price objective on Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a research report on Tuesday, October 1st. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. Finally, Mizuho lowered their price objective on Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, Hologic presently has a consensus rating of “Moderate Buy” and an average price target of $89.91.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.